title: Rituximab-induced Acute Thrombocytopenia in High Tumor Burden Follicular Lymphoma.
abstract: Rituximab-induced acute thrombocytopenia (RIAT), a rare complication of rituximab administration, has not yet been described in follicular lymphoma (FL). A 65-year-old man received rituximab for the treatment of high tumor burden follicular lymphoma in the leukemic phase. The next day, his platelet count abruptly dropped from 85,000 to 5,000/μL, which spontaneously recovered in a few days without specific treatment. We speculate that the occurrence of infusion-related cytokine release syndrome in rituximab-sensitive high tumor burden FL contributed to the development of RIAT. Frequent monitoring of the platelet count is advisable for select patients considered to be at a high risk for RIAT.
authors.affiliation: Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ureshino
authors.forename: Atsujiro
authors.initials: A
authors.lastname: Nishioka
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kojima
authors.forename: Motoaki
authors.initials: M
authors.lastname: Suzuki
authors.forename: Haruna
authors.initials: H
authors.lastname: Kizuka
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Sano
authors.forename: Takero
authors.initials: T
authors.lastname: Shindo
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Kubota
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ando
authors.forename: Shinya
authors.initials: S
authors.lastname: Kimura
mesh_terms: D000208:Acute Disease; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy; D008297:Male; D010976:Platelet Count; D000069283:Rituximab / Q000008:administration & dosage / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D000970:Antineoplastic Agents; D000069283:Rituximab